A positive correlation between homocysteine and brachial-ankle pulse wave velocity in patients with systemic lupus erythematosus

Clinical Rheumatology

Volumn 25, Issue 3, 2006, Pages 285-290

  Tso, Tim K ^a   Huang, Hui Yu ^a   Chang, Chen Kang ^b   Huang, Wen Nan ^c,d  

^a SHIH CHIEN UNIVERSITY   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY OF SPORT   (Taiwan)

^c TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^d CHUNG SHAN MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Atherosclerosis; Homocysteine; Pulse wave velocity; Systemic lupus erythematosus; Vascular stiffness

Indexed keywords

CARDIOLIPIN ANTIBODY; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; HOMOCYSTEINE; HYDROXYCHLOROQUINE; PREDNISONE;

ADULT; ANKLE BRACHIAL INDEX; ANTIBODY DETECTION; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; BLOOD VESSEL COMPLIANCE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE ASSOCIATION; FEMALE; HUMAN; HYPERHOMOCYSTEINEMIA; MAJOR CLINICAL STUDY; MORTALITY; NON INVASIVE MEASUREMENT; PATIENT CODING; PRIORITY JOURNAL; PULSE WAVE; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; ANKLE; ANTIBODIES, ANTICARDIOLIPIN; ANTIBODIES, ANTINUCLEAR; ATHEROSCLEROSIS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DNA; FEMALE; HEALTH STATUS; HOMOCYSTEINE; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; PULSATILE FLOW; SEVERITY OF ILLNESS INDEX;

EID: 33645759265     PISSN: 07703198     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10067-005-0063-7     Document Type: Article

References (43)

1. Steinberg AD, Klinman DM (1988) Pathogenesis of systemic lupus erythematosus. Rheum Dis Clin North Am 14:25-41
2. Abu-Shakra M, Urowitz MB, Gladman DD, Gough J (1995) Mortality studies in systemic lupus erythematosus: Results from a single center. I. Causes of death. J Rheumatol 22:1259-1264
3. Ward MM (1999) Premature morbidity from cardiovascular and cerebrovascular diseases in women with systemic lupus erythematosus. Arthritis Rheum 42:338-346
4. Stein JH, McBride PE (1998) Hyperhomocysteinemia and atherosclerotic vascular disease: Pathophysiology, screening and treatment. Arch Intern Med 158:1301-1306
5. Hultberg B, Andersson A, Sterner G (1993) Plasma homocysteine in renal failure. Clin Nephrol 40:230-234
6. Haagsma CJ, Blom HJ, Piet LCM et al (1999) Influence of sulphasalazine, methotrexate, and the combination of both on plasma homocysteine concentrations in patients with rheumatoid arthritis. Ann Rheum Dis 58:79-84
7. Refai TMK, Al-Salem IH, Nkansa-Dwamena D, Al-Salem MH (2002) Hyperhomocysteinaemia and risk of thrombosis in systemic lupus erythematosus patients. Clin Rheumatol 21:457-461
8. Petri M, Roubenoff R, Dallal GE et al (1996) Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet 348:1120-1124
9. Fijnheer R, Roest M, Haas FJ et al (1998) Homocysteine, methylenetetrahydrofolate reductase polymorphism, antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: A retrospective cohort study. J Rheumatol 25:1737-1742
10. Laurent S, Boutouyrie P, Asmar R et al (2001) Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension 37:1236-1241
11. Meaume S, Benetos A, Henry OF, Rudnichi A, Safar ME (2001) Aortic pulse wave velocity predicts cardiovascular mortality in subjects >70 years of age. Arterioscler Thromb Vasc Biol 21:2046-2050
12. Shoji T, Emoto M, Shinohara K et al (2001) Diabetes mellitus, aortic stiffness, and cardiovascular mortality in end-stage renal disease. J Am Soc Nephrol 12:2117-2124
13. van Popele NM, Grobbee DE, Bots ML et al (2001) Association between arterial stiffness and atherosclerosis: The Rotterdam study. Stroke 32:454-460
14. Yamashina A, Tomiyama H, Takeda K et al (2002) Validity, reproducibility, and clinical significance of noninvasive brachial-ankle pulse wave velocity measurement. Hypertens Res 25:359-364
15. Aso K, Miyata M, Kubo T et al (2003) Brachial-ankle pulse wave velocity is useful for evaluation of complications in type 2 diabetic patients. Hypertens Res 26:807-813
16. Yokoyama H, Hirasawa K, Aoki T, Ishiyama M, Koyama K (2003) Brachial-ankle pulse wave velocity measured automatically by oscillometric method is elevated in diabetic patients with incipient nephropathy. Diabet Med 20:942-945
17. Choi KM, Lee KW, Seo JA et al (2004) Relationship between brachial-ankle pulse wave velocity and cardiovascular risk factors of the metabolic syndrome. Diabetes Res Clin Pract 66:57-61
18. Ohnishi H, Saitoh S, Takagi S et al (2003) Pulse wave velocity as an indicator of atherosclerosis in impaired fasting glucose: The tanno and sobetsu study. Diabetes Care 26:437-440
19. Munakata M, Ito N, Nunokawa T, Yoshinaga K (2003) Utility of automated brachial ankle pulse wave velocity measurements in hypertensive patients. Am J Hypertens 16:653-657
20. Yamashina A, Tomiyama H, Arai T et al (2003) Brachial-ankle pulse wave velocity as a marker of atherosclerotic vascular damage and cardiovascular risk. Hypertens Res 26:615-622
21. Imanishi R, Seto S, Toda G et al (2004) High brachial-ankle pulse wave velocity is an independent predictor of the presence of coronary artery disease in men. Hypertens Res 27:71-78
22. Refsum H, Ueland PM, Nygard O, Vollset SE (1998) Homocysteine and cardiovascular disease. Annu Rev Med 49:31-62
23. Eikelboom JW, Lonn E, Genest J Jr, Hankey G, Yusuf S (1999) Homocysteine and cardiovascular disease: A critical review of the epidemiologic evidence. Ann Intern Med 131:363-375
24. Hsu TS, Hsu LA, Chang CJ et al (2001) Importance of hyperhomocysteinemia as a risk factor for venous thromboembolism in a Taiwanese population. A case-control study. Thromb Res 102:387-395
25. Welch GN, Loscalzo JN (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042-1050
26. Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Rueda M, Aguirre C (2004) Homocysteine, antiphospholipid antibodies and risk of thrombosis in patients with systemic lupus erythematosus. Lupus 13:927-933
27. Martinez-Berriotxoa A, Ruiz-Irastorza G, Egurbide MV, Rueda M, Aguirre C (2003) Plasma homocysteine levels in patients with systemic lupus erythematosus. Med Clin (Barc) 120:681-685
28. Tan EM, Cohen AS, Fries JF et al (1982) The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 25:1271-1277
29. Friedewald WT, Levy RI, Fredrickson DS (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma without use of the preparative ultracentrifuge. Clin Chem 18:499-502
30. Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (2001) Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults, adult treatment panel III. JAMA 285:2486-2497
31. National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult treatment panel III) (2002) Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III) final report. Circulation 106:3143-3421
32. Bombardier C, Gladman DD, Urowitz MB et al (1992) Derivation of the SLEDAI: A disease activity index for lupus patients. Arthritis Rheum 35:630-640
33. Chang DM, Lan JL, Lin HY, Luo SF (2002) Dehydroepiandrosterone treatment of women with mild-to-moderate systemic lupus erythematosus. Arthritis Rheum 46:2924-2927
34. Tso TK, Huang HY, Chang CK, Liao YJ, Huang WN (2004) Clinical evaluation of insulin resistance and β-cell function by the homeostasis model assessment in patients with systemic lupus erythematosus. Clin Rheumatol 23:416-420
35. Hayashi C, Ogawa O, Kubo S, Mitsuhashi N, Onuma T, Kawamori R (2004) Ankle brachial pressure index and carotid intima-media thickness as atherosclerosis markers in Japanese diabetics. Diabetes Res Clin Pract 66:269-275
36. Clarke R, Daly L, Robinson K et al (1991) Hyperhomocysteinemia: An independent risk factor for vascular disease. N Engl J Med 324:1149-1155
37. Ueland PM, Refsum H, Beresford SAA, Vollset SE (2000) The controversy over homocysteine and cardiovascular risk. Am J Clin Nutr 72:324-332
38. Welch GN, Loscalzo JN (1998) Homocysteine and atherothrombosis. N Engl J Med 338:1042-1050
39. Boushey CJ, Beresford SAA, Omenn GS, Motulsky AG (1995) A quantitative assessment of plasma homocysteine as a risk factor for vascular disease, probable benefits of increasing folic acid intakes. J Am Med Assoc 274:1049-1057
40. den Heijer M, Koster T, Blom HJ et al (1996) Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 334:759-762
41. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S (2001) Vascular stiffness in women with systemic lupus erythematosus. Hypertension 37:1075-1082
42. Hossain GS, van Thienen JV, Werstuck GH et al (2003) TDAG51 is induced by homocysteine, promotes detachment-mediated programmed cell death, and contributes to the development of atherosclerosis in hyperhomocysteinemia. J Biol Chem 278:30317-30327
43. Buemi M, Marino D, Di Pasquale G et al (2001) Effects of homocysteine on proliferation, necrosis and apoptosis of vascular smooth muscle cells in culture and influence of folic acid. Thromb Res 104:207-213